Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Inspire Medical Systems (INSP)
NYSE:INSP
RESEARCH TOOLSreports
Inspire Medical Systems (INSP) Stock Price & Analysis
638 Followers
INSP Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$123.27 - $330.00
Previous Close$249.72
Volume354.96K
Average Volume (3M)503.04K
Market Cap
$7.57B
Enterprise Value$7.13B
Total Cash (Recent Filing)$460.38M
Total Debt (Recent Filing)$24.85M
Price to Earnings (P/E)-336.7
Beta1.25
Next Earnings
May 07, 2024EPS Estimate
-$0.65Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.74
Shares Outstanding29,585,104
10 Day Avg. Volume369,627
30 Day Avg. Volume503,037
Standard Deviation0.15
R-Squared0.23
Alpha0.02
Financial Highlights & Ratios
Price to Book (P/B)12.98
Price to Sales (P/S)11.82
Price to Cash Flow (P/CF)107.60
P/FCF Ratio201.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue11.70
Enterprise Value/Gross Profit13.50
Enterprise Value/Ebitda1.86K
Forecast
1Y Price Target
$254.85Price Target Upside2.05% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering15
Inspire Medical Systems News
Bulls Say, Bears Say
Bulls Say
Clinical Trial OutcomesTirzepatide met all primary and secondary endpoints in the SURMOUNT-OSA study, showing efficacy and safety in treating moderate-to-severe OSA patients.
Market PenetrationINSP holds the dominant share in the fast growth, $10B US hypoglossal nerve stim (HGNS) market for OSA, which is only 5% penetrated.
Stock Performance OutlookAnalyst maintains a Buy rating with a price objective of 265.00 USD, implying a significant upside potential from the current price of 195.23 USD.
Bears Say
Clinical Trial DataConcerns remain that tirzepatide will disrupt INSP implants in the near-term.
Insurance And Policy ChangesThe recently announced policy change from UnitedHealth requiring Inspire patients to first try and fail oral appliance therapy introduces an additional headwind for INSP.
Regulatory And Competitive LandscapePotential FDA approval of tirzepatide in OSA presents a competitive challenge for INSP.
---
Ownership Overview
6.11% Insiders
56.62% Mutual Funds
23.03% Other Institutional Investors
14.25% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Legal & RegulatoryLitigation, compliance, new legislation, and taxation risks
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
INSP FAQ
What was Inspire Medical Systems’s price range in the past 12 months?
Inspire Medical Systems lowest stock price was $123.27 and its highest was $330.00 in the past 12 months.
What is Inspire Medical Systems’s market cap?
Currently, no data Available
When is Inspire Medical Systems’s upcoming earnings report date?
Inspire Medical Systems’s upcoming earnings report date is May 07, 2024 which is yesterday.
How were Inspire Medical Systems’s earnings last quarter?
Inspire Medical Systems released its earnings results on Feb 06, 2024. The company reported $0.49 earnings per share for the quarter, beating the consensus estimate of -$0.053 by $0.543.
Is Inspire Medical Systems overvalued?
According to Wall Street analysts Inspire Medical Systems’s price is currently Undervalued.
Does Inspire Medical Systems pay dividends?
Inspire Medical Systems does not currently pay dividends.
What is Inspire Medical Systems’s EPS estimate?
Inspire Medical Systems’s EPS estimate is -$0.65.
How many shares outstanding does Inspire Medical Systems have?
Inspire Medical Systems has 30,297,312 shares outstanding.
What happened to Inspire Medical Systems’s price movement after its last earnings report?
Inspire Medical Systems reported an EPS of $0.49 in its last earnings report, beating expectations of -$0.053. Following the earnings report the stock price went down -10.549%.
Which hedge fund is a major shareholder of Inspire Medical Systems?
Among the largest hedge funds holding Inspire Medical Systems’s share is Farallon Capital Management, L.L.C.. It holds Inspire Medical Systems’s shares valued at 174M.
---
Inspire Medical Systems Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$254.85 (2.05% Upside)
$254.85 (2.05% Upside)
Blogger Sentiment
Bullish
INSP Sentiment 83%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 731.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $10.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 6.3%
Last 30 Days ▲ 6.3%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-9.26%
12-Months-Change
Fundamentals
Return on Equity
-3.96%
Trailing 12-Months
Asset Growth
19.82%
Trailing 12-Months
Company Description
Inspire Medical Systems
Inspire Medical Systems, Inc. engages in the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea. It offers inspire therapy, which consists of a remote control and implantable components that includes pressure sensing lead, a neurostimulator, and a stimulation lead. The company was founded by Timothy P. Herbert in November 2007 and is headquartered in Golden Valley, MN.
---
INSP Company Deck
---
INSP Earnings Call
Q4 2024
0:00 / 0:00
---
INSP Revenue Breakdown
97.02% U.S.
2.98% Other
---
INSP Stock 12 Month Forecast
Average Price Target
$254.85
▲(2.05% Upside)
Technical Analysis
Best Analysts Covering INSP
1 Year
1 Year Success Rate
9/13 ratings generated profit
1 Year Average Return
+26.73%
reiterated a buy rating 21 days ago
Copying Frank Takkinen's trades and holding each position for 1 Year would result in 69.23% of your transactions generating a profit, with an average return of +26.73% per trade.
---